215 related articles for article (PubMed ID: 27420181)
21. Long-term treatment outcomes in Gaucher disease.
Charrow J; Scott CR
Am J Hematol; 2015 Jul; 90 Suppl 1():S19-24. PubMed ID: 26096742
[TBL] [Abstract][Full Text] [Related]
22. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
Tóth J; Szücs FZ; Benkö K; Maródi L
Orv Hetil; 2003 Apr; 144(16):749-55. PubMed ID: 12778625
[TBL] [Abstract][Full Text] [Related]
23. Glucosylsphingosine is a key biomarker of Gaucher disease.
Murugesan V; Chuang WL; Liu J; Lischuk A; Kacena K; Lin H; Pastores GM; Yang R; Keutzer J; Zhang K; Mistry PK
Am J Hematol; 2016 Nov; 91(11):1082-1089. PubMed ID: 27441734
[TBL] [Abstract][Full Text] [Related]
24. Re-evaluation of bone pain in patients with type 1 Gaucher disease suggests that bone crises occur in small bones as well as long bones.
Baris HN; Weisz Hubshman M; Bar-Sever Z; Kornreich L; Shkalim Zemer V; Cohen IJ
Blood Cells Mol Dis; 2016 Sep; 60():65-72. PubMed ID: 26051481
[TBL] [Abstract][Full Text] [Related]
25. [Gaucher disease: MR evaluation of bone marrow features during treatment with enzyme replacement].
Poll LW; vom Dahl S; Koch JA; Börner D; Willers R; Cohnen M; Jung G; Scherer A; Niederau C; Häussinger D; Mödder U
Rofo; 2001 Oct; 173(10):931-7. PubMed ID: 11588682
[TBL] [Abstract][Full Text] [Related]
26. Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center.
Basiri M; Ghaffari ME; Ruan J; Murugesan V; Kleytman N; Belinsky G; Akhavan A; Lischuk A; Guo L; Klinger K; Mistry PK
Elife; 2023 May; 12():. PubMed ID: 37249220
[TBL] [Abstract][Full Text] [Related]
27. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results.
Poll LW; Koch JA; vom Dahl S; Willers R; Scherer A; Boerner D; Niederau C; Häussinger D; Mödder U
Skeletal Radiol; 2001 Sep; 30(9):496-503. PubMed ID: 11587517
[TBL] [Abstract][Full Text] [Related]
28. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
Pastores GM; Elstein D; Hrebícek M; Zimran A
Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic goals in Gaucher disease.
Mistry P; Germain DP
Rev Med Interne; 2006 Mar; 27 Suppl 1():S30-8. PubMed ID: 16644400
[TBL] [Abstract][Full Text] [Related]
30. 99mTc-sestamibi scintigraphy to monitor the long-term efficacy of enzyme replacement therapy on bone marrow infiltration in patients with Gaucher disease.
Erba PA; Minichilli F; Giona F; Linari S; Dambrosia J; Pierini A; Filocamo M; Di Rocco M; Buffoni F; Brady RO; Mariani G
J Nucl Med; 2013 Oct; 54(10):1717-24. PubMed ID: 23990684
[TBL] [Abstract][Full Text] [Related]
31. [Quality of life of 22 patients with type 1 Gaucher disease after enzyme replacement therapy].
Li HM; Zhang RX; Long ZB; Du YL; Chen M; Zhuang JL; Qiu ZQ; Han B
Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):287-291. PubMed ID: 32447931
[No Abstract] [Full Text] [Related]
32. Skeletal aspects of Gaucher disease: a review.
Wenstrup RJ; Roca-Espiau M; Weinreb NJ; Bembi B
Br J Radiol; 2002; 75 Suppl 1():A2-12. PubMed ID: 12036828
[TBL] [Abstract][Full Text] [Related]
33. Skeletal complications of type I Gaucher disease: the magnetic resonance features.
Cremin BJ; Davey H; Goldblatt J
Clin Radiol; 1990 Apr; 41(4):244-7. PubMed ID: 2340694
[TBL] [Abstract][Full Text] [Related]
34. Relationship Between Glucocerebrosidase Activity and Clinical Response to Enzyme Replacement Therapy in Patients With Gaucher Disease Type I.
Gras-Colomer E; Martínez-Gómez MA; Climente-Martí M; Fernandez-Zarzoso M; Almela-Tejedo M; Giner-Galvañ V; Marcos-Rodríguez JA; Rodríguez-Fernández A; Torralba-Cabeza MÁ; Merino-Sanjuan M
Basic Clin Pharmacol Toxicol; 2018 Jul; 123(1):65-71. PubMed ID: 29418074
[TBL] [Abstract][Full Text] [Related]
35. Use of plain radiography to optimize skeletal outcomes in children with type 1 Gaucher disease in Brazil.
Mota RM; Mankin H
J Pediatr Orthop; 2007; 27(3):347-50. PubMed ID: 17414023
[TBL] [Abstract][Full Text] [Related]
36. [Bone manifestations of Gaucher's disease in Mexican patients].
Blass PJ
Acta Ortop Mex; 2010; 24(5):351-8. PubMed ID: 21246808
[TBL] [Abstract][Full Text] [Related]
37. Severe skeletal complications in Japanese patients with type 1 Gaucher disease.
Ida H; Rennert OM; Kato S; Ueda T; Oishi K; Maekawa K; Eto Y
J Inherit Metab Dis; 1999 Feb; 22(1):63-73. PubMed ID: 10070619
[TBL] [Abstract][Full Text] [Related]
38. Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications.
van Dussen L; Biegstraaten M; Dijkgraaf MG; Hollak CE
Orphanet J Rare Dis; 2014 Jul; 9():112. PubMed ID: 25056340
[TBL] [Abstract][Full Text] [Related]
39. [Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment].
Javier RM; Hachulla E
Presse Med; 2007 Dec; 36(12 Pt 3):1971-84. PubMed ID: 17498916
[TBL] [Abstract][Full Text] [Related]
40. Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement.
Elstein D; Hadas-Halpern I; Itzchaki M; Lahad A; Abrahamov A; Zimran A
Blood Cells Mol Dis; 1996; 22(2):104-11; discussion 112-4. PubMed ID: 8931951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
